Serum EPCA Level and Its Association with Prostate Cancer Progression
Author Information
Author(s): Zhao Zhigang, Ma Wenjing, Zeng Guohua, Qi Defeng, Ou Lili, Liang Yeping
Primary Institution: The First Affiliated Hospital of Guangzhou Medical College
Hypothesis
The study aims to evaluate the clinical value of serum EPCA levels in predicting disease progression in prostate cancer patients.
Conclusion
Serum EPCA level is significantly elevated in prostate cancer patients and correlates with poor prognosis, indicating its potential as a predictive marker for disease progression.
Supporting Evidence
- Serum EPCA levels were significantly higher in prostate cancer patients compared to healthy controls.
- Patients with metastatic prostate cancer had the highest serum EPCA levels.
- Elevated serum EPCA levels were positively correlated with Gleason score and clinical stage.
Takeaway
This study found that higher levels of a protein called EPCA in the blood can help doctors predict how prostate cancer will progress in patients.
Methodology
Serum EPCA levels were measured using ELISA in 128 prostate cancer patients and compared with 40 healthy controls.
Limitations
The study had a relatively small sample size and a short follow-up period.
Participant Demographics
Patients included 128 men with prostate cancer, aged 46-78 years, with a mean age of 63.3 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%CI: 2.070–6.035
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website